SPECIALTY GUIDELINE MANAGEMENT

Supprelin LA (histrelin acetate)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indication

Supprelin LA is indicated for the treatment of children with central precocious puberty (CPP).

B. Compendial Use

1. Gender dysphoria (also known as gender non-conforming or transgender persons)
   
   NOTE: Some plans may opt-out of coverage for gender dysphoria.

2. Preservation of ovarian function

3. Prevention of recurrent menstrual related attacks in acute porphyria

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Central precocious puberty (CPP)

1. Authorization up to age 12 may be granted for the treatment of CPP in a female member when all of the following criteria are met:
   a. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging, such as computed tomography (CT scan), magnetic resonance imaging (MRI), or ultrasound.
   b. The diagnosis of CPP has been confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test or a pubertal level of a third generation luteinizing hormone (LH) assay.
   c. The assessment of bone age versus chronological age supports the diagnosis of CPP.
   d. The member was less than 8 years of age at the onset of secondary sexual characteristics.

2. Authorization up to age 13 may be granted for the treatment of CPP in a male member when all of the following criteria are met:
   a. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging, such as CT scan, MRI, or ultrasound.
   b. The diagnosis of CPP has been confirmed by a pubertal response to a GnRH agonist test or a pubertal level of a third generation LH assay.
   c. The assessment of bone age versus chronological age supports the diagnosis of CPP.
   d. The member was less than 8 years of age at the onset of secondary sexual characteristics.

B. Gender dysphoria

1. Authorization of 12 months may be granted for pubertal suppression in preparation for gender reassignment in an adolescent member when all of the following criteria are met:
   a. The member has a diagnosis of gender dysphoria.
   b. The member has reached Tanner stage 2 of puberty.
2. Authorization of 12 months may be granted for gender reassignment in an adult member when all of the following criteria are met:
   a. The member has a diagnosis of gender dysphoria.
   b. The member will receive Supprelin LA concomitantly with cross sex hormones.

C. Preservation of ovarian function
   Authorization of 3 months may be granted for preservation of ovarian function when the member is premenopausal and undergoing chemotherapy.

D. Prevention of recurrent menstrual related attacks in acute porphyria
   Authorization of 12 months may be granted for prevention of recurrent menstrual related attacks in members with acute porphyria when the requested medication is prescribed by or in consultation with a physician experienced in the management of porphyrias.

III. CONTINUATION OF THERAPY

A. Central precocious puberty (CPP)
   1. Authorization up to age 12 may be granted for continuation of therapy for CPP in a female member if the member is currently less than 12 years of age.
   2. Authorization up to age 13 may be granted for continuation of therapy for CPP in a male member if the member is currently less than 13 years of age.

B. Gender Dysphoria
   All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

C. All other indications
   All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES


